Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Imatinib in Intermediate-Risk GIST With High Genomic Grade Index
2024-515432-71-00Phase 3Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in gastrointestinal stromal tumor (GIST) comparing Adjuvant imatinib with Control (observation) (2 arms). Primary endpoint: Metastatic relapse rate at 2 years. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2024-515432-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515432-71-00.